Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

PURPOSE: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. PATIENTS AND METHODS: In total, 477 patients with CD2...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Gisselbrecht, Christian, Schmitz, Norbert, Mounier, Nicolas, Singh Gill, Devinder, Linch, David C., Trneny, Marek, Bosly, Andre, Milpied, Noel J., Radford, John, Ketterer, Nicolas, Shpilberg, Ofer, Dührsen, Ulrich, Hagberg, Hans, Ma, David D., Viardot, Andreas, Lowenthal, Ray, Brière, Josette, Salles, Gilles, Moskowitz, Craig H., Glass, Bertram
Format: Artigo
Język:Inglês
Wydane: American Society of Clinical Oncology 2012
Hasła przedmiotowe:
Original Reports
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646314/
https://ncbi.nlm.nih.gov/pubmed/23091101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.41.9416
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy